Harmony Biosciences Holdings, Inc. (HRMY)

NASDAQ: HRMY · IEX Real-Time Price · USD
35.62 -1.06 (-2.89%)
Jan 18, 2022 2:54 PM EST - Market open
Market Cap2.08B
Revenue (ttm)270.52M
Net Income (ttm)11.68M
Shares Out58.47M
EPS (ttm)0.20
PE Ratio181.73
Forward PE22.42
Dividendn/a
Ex-Dividend Daten/a
Volume134,099
Open36.38
Previous Close36.68
Day's Range35.00 - 36.49
52-Week Range25.09 - 45.89
Betan/a
AnalystsBuy
Price Target57.00 (+60.0%)
Earnings DateNov 9, 2021

About HRMY

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy in the United States. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvani...

IndustryBiotechnology
IPO DateAug 19, 2020
Employees150
Stock ExchangeNASDAQ
Ticker SymbolHRMY
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for HRMY stock is "Buy." The 12-month stock price forecast is 57.00, which is an increase of 60.02% from the latest price.

Price Target
$57.00
(60.02% upside)
Analyst Consensus: Buy

News

Harmony Biosciences to Participate in 40th Annual J.P. Morgan Healthcare Conference

PLYMOUTH MEETING, Pa., Jan. 5, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapi...

1 week ago - PRNewsWire

Harmony Biosciences to be Added to the Nasdaq Biotech Index

PLYMOUTH MEETING, Pa., Dec. 17, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therap...

1 month ago - PRNewsWire

Harmony Biosciences Publishes Pitolisant Efficacy Data In CNS Drugs

PLYMOUTH MEETING, Pa., Dec. 13, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therap...

1 month ago - PRNewsWire

Harmony Biosciences Announces Plans To Initiate Phase 3 Clinical Trial For Treatment Of Idiopathic Hypersomnia

PLYMOUTH MEETING, Pa., Dec. 1, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapi...

1 month ago - PRNewsWire

Harmony Biosciences Appoints Linda Szyper To Its Board Of Directors

PLYMOUTH MEETING, Pa., Nov. 22, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing ...

1 month ago - PRNewsWire

Harmony Biosciences To Participate In Two Investor Conferences In November

PLYMOUTH MEETING, Pa., Nov. 11, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therap...

2 months ago - PRNewsWire

Harmony Biosciences Holdings, Inc. (HRMY) Tops Q3 Earnings and Revenue Estimates

Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of 88.89% and 1.81%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead f...

2 months ago - Zacks Investment Research

Harmony Biosciences Reports Third Quarter 2021 Financial Results and Business Updates

WAKIX® (pitolisant) Net Revenue of $80.7 Million for Third Quarter 2021 Increase of 77% vs. the Same Period in 2020

2 months ago - GlobeNewsWire

Harmony Biosciences Holdings, Inc. (HRMY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Harmony Biosciences Holdings, Inc. (HRMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Harmony Biosciences Announces Date of Third Quarter 2021 Financial Results

PLYMOUTH MEETING, Pa., Oct. 26, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing ...

2 months ago - PRNewsWire

Harmony Biosciences to be Added to the S&P SmallCap 600® Index

PLYMOUTH MEETING, Pa., Oct. 21, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing ...

2 months ago - PRNewsWire

Harmony Biosciences Holdings, Inc. (HRMY) Surges 10.2%: Is This an Indication of Further Gains?

Harmony Biosciences Holdings, Inc. (HRMY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving hig...

2 months ago - Zacks Investment Research

Why Harmony Biosciences Stock Is Up 15% Today

The young biopharma outfit is set to become part of a major market index, which means a buying spree is on the radar.

2 months ago - The Motley Fool

Kite Realty Group Trust Set to Join S&P MidCap 400; Harmony Biosciences Holdings & LendingTree to Join S&P SmallCap 600

NEW YORK, Oct. 18, 2021 /PRNewswire/ -- S&P SmallCap 600 constituent Kite Realty Group Trust (NYSE:KRG) will replace LendingTree Inc. (NASD:TREE) in the S&P MidCap 400, LendingTree will replace Kite Rea...

Other symbols:KRGTREE
2 months ago - PRNewsWire

5 Stocks for Higher Returns as Analysts Initiate Coverage

Increased analyst coverage over the past few weeks might lead to solid price appreciation for stocks like Alpha and Omega (AOSL), Preferred Apartment (APTS), Hut 8 Mining (HUT), GCM (GCMG) & Harmony Bio...

Other symbols:AOSLAPTSGCMGHUT
3 months ago - Zacks Investment Research

Harmony Biosciences Announces Winners of Patients at the Heart and Progress at the Heart on Third Annual World Narcol...

PLYMOUTH MEETING, Pa., Sept. 22, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative thera...

3 months ago - PRNewsWire

Harmony Biosciences To Participate In Three Investor Conferences In September

PLYMOUTH MEETING, Pa., Sept. 2, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therap...

4 months ago - PRNewsWire

Harmony Biosciences Stock Is Trading Higher On $330M Financing Deal With Blackstone, Q2 Earning Beat Estimates

Harmony Biosciences Holdings Inc (NASDAQ: HRMY) has entered into a $330 million financing collaboration with The Blackstone Group Inc (NYSE: BX). The financing deal includes up to $300 million in debt c...

5 months ago - Benzinga

Harmony Biosciences Reports Second Quarter 2021 Financial Results and Business Updates

WAKIX® (pitolisant) Net Revenue of $73.8 Million for Second Quarter 2021 vs. $38 Million for the Same Period in 2020

5 months ago - GlobeNewsWire

Harmony Biosciences And Blackstone Enter Into Strategic Financing Collaboration

PLYMOUTH MEETING, Pa. and NEW YORK, Aug. 10, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing inno...

Other symbols:BX
5 months ago - PRNewsWire

Harmony Biosciences Acquires Asset With Novel Mechanism Of Action For The Potential Treatment Of Narcolepsy And Other...

PLYMOUTH MEETING, Pa., Aug. 9, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapi...

5 months ago - PRNewsWire

John C. Jacobs, President And CEO Of Harmony Biosciences, Named An Ernst & Young (EY) Entrepreneur Of The Year 2021 G...

PLYMOUTH MEEETING, Pa., July 29, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative thera...

5 months ago - PRNewsWire

Harmony Biosciences Announces Date Of Second Quarter 2021 Financial Results

PLYMOUTH MEETING, Pa., July 27, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing ...

5 months ago - PRNewsWire

Harmony Biosciences Initiates A Phase 2 Clinical Trial In Myotonic Dystrophy

PLYMOUTH MEETING, Pa., June 29, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therap...

6 months ago - PRNewsWire

Harmony Biosciences Presents New Analysis Of Clinical Impact For WAKIX® (pitolisant) At The SLEEP 2021 Annual Meeting

PLYMOUTH MEETING, Pa., June 10, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therap...

7 months ago - PRNewsWire